The Need

Cereblon (CRBN) is a 51 kDa protein encoded by the gene CRBN. This protein is a target of the immunomodulatory drugs thalidomide, lenalidomide, and pomalidomide that show substantial activity in several hematologic cancers, including multiple myeloma, acute myeloid leukemia, and chronic lymphocytic leukemia. Cereblon protein is known to bind calcium-activated potassium channels (KCNMA1 subtype) and mutations in the CRBN gene are linked to cognitive defects, including intellectual disability. Cereblon also interacts with E3 ubiquitin ligase and may play a key role in limb outgrowth in embryos.

For reasons that are unclear, all commercially available antibodies for CRBN possess low specificity and effectiveness in immunological assays. Due to the rapidly growing interest in detecting CRBN, there is currently a strong demand for a high-quality CRBN antibody.

The Technology

Researchers at The Ohio State University, led by Dr. David Lucas, developed three hybridoma cell lines (4A7H6, 3B12F7, 4E11E2) that produce novel monoclonal antibodies, recognize mammalian CRBN, and are suitable for immunohistochemistry and western blotting.

Commercial Applications

• Immunoassay development

Benefits/Advantages

• High-quality antibodies suitable for a variety of testing
• (OTHER)
• (OTHER)